Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.54 |
| ▸ | MAOB | P27338 | 8/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.49 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135609 | 0.85 | KDM1A (0.63) | KDM1AMAOBMAOA | |
| SCHEMBL4135605 | 0.85 | KDM1A (0.63) | KDM1AMAOBMAOA | |
| SCHEMBL12870250 | 0.85 | KDM1A (0.63) | KDM1AMAOBMAOA | |
| SCHEMBL25069642 | 0.85 | KDM1A (0.63) | KDM1AMAOBMAOA | |
| SCHEMBL25069889 | 0.81 | KDM1A (0.69) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL25069887 | 0.81 | KDM1A (0.69) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL14880419 | 0.78 | KDM1A (0.54) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL900481 | 0.76 | KDM1A (0.72) | KDM1AMAOBMAOACISD1KDM1B | |
| SCHEMBL25069675 | 0.76 | GRIA4 (0.51) | KDM1AMAOBMAOA | |
| SCHEMBL25069500 | 0.76 | GRIA4 (0.51) | KDM1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | KDM1A 2576/4885MAOB 4262/4885MAOA 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.